ribociclib will boost the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
enzalutamide will lower the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers could lead on into a minimize in fentanyl plasma concentrations, insufficient efficacy or, maybe, enhancement of a withdrawal syndrome in a very affected person who's got produced Bodily dependence to fentanyl.
fentanyl iontophoretic transdermal system and fentanyl both equally improve sedation. Prevent or Use Alternate Drug. Limit use to patients for whom choice treatment options are inadequate
Cessation of benzodiazepines or other CNS depressants is preferred in many cases. In a few cases, checking at a higher level of care for tapering CNS depressants can be suitable. In others, slowly tapering a patient off of a prescribed benzodiazepine or other CNS depressant or reducing to the lowest effective dose can be correct.
Voxelotor boosts systemic exposure of delicate CYP3A4 substrates. Avoid coadministration with delicate CYP3A4 substrates with a slender therapeutic index. Consider dose reduction in the delicate CYP3A4 substrate(s) if not able to avoid.
If coadministration of CYP3A4 inhibitors with fentanyl is necessary, keep track of patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments till stable drug effects are reached.
nevirapine will decrease the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Intently. Coadministration of fentanyl with fentanyl tab CYP3A4 inducers may lead into a reduce in fentanyl plasma concentrations, not enough efficacy or, maybe, growth of the withdrawal syndrome in the patient that has produced Bodily dependence to fentanyl.
fentanyl, atropine. Both increases toxicity from the other by pharmacodynamic synergism. Modify Therapy/Watch Closely. Coadministration of fentanyl with anticholinergics could maximize risk for urinary retention and/or serious constipation, which may bring on paralytic ileus.
Keep track of Closely (1)belzutifan will reduce the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
talquetamab will boost the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Talquetamab causes cytokine release syndrome (CRS) that may suppress activity of CYP enzymes, causing amplified exposure of CYP substrates.
fentanyl, clemastine. Either improves toxicity on the other by pharmacodynamic synergism. Modify Therapy/Keep track of Intently. Coadministration of fentanyl with anticholinergics could increase risk for urinary retention and/or critical constipation, which may produce paralytic ileus.
Watch Carefully (1)teclistamab will enhance the level or effect of fentanyl by altering metabolism. Use Warning/Keep an eye on. Teclistamab causes release of cytokines which will suppress action of CYP450 enzymes, resulting in increased exposure of CYP substrates.
Narcotic agonist-analgesic of opiate receptors; inhibits ascending pain pathways, So altering reaction to pain; will increase pain threshold; creates analgesia, respiratory depression, and sedation
If coadministration of CYP3A4 inhibitors with fentanyl is essential, keep track of patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose changes until eventually stable drug effects are attained.